Therapeutic options of post-COVID-19 related olfactory dysfunction: a systematic review and meta-analysis. (2023)
“we propose that OT should be the primary treatment in patients with persistent post-COVID-19 olfactory loss.”
At a glance, by condition
Long COVID: B May help
Based on the strongest evidence, compared with another group, not randomised (low certainty), for smell and taste loss.
3 outcomes rated · see each below
Both together: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty), for smell and taste loss.
1 outcome rated · see each below
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: For long COVID, smell training (olfactory training) may help, but the evidence is still limited. For long COVID and ME/CFS studied together, smell training (olfactory training) might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
Why this grade: Mixed results, very low certainty, from controlled studies: risk of bias couldn't be judged for most results (ROBINS-I: no information); randomised trials found little or no difference.
Randomised trials7 studies · 367 people with results
No clear difference in smell and taste loss.
The evidence is very uncertain about the effect of smell training (olfactory training) on smell and taste loss in long COVID. Little or no difference · very low certainty D
How big was the difference?
0, very small. The effect size compares smell training (olfactory training) with placebo.
Compared with another group, not randomised2 studies · 118 people with results
Smell and taste loss improved more than in the comparison group.
Smell training (olfactory training) may reduce smell and taste loss in long COVID. Improvement · low certainty B
Studies with no comparison group6 studies · 644 people with results
Smell and taste loss improved.
The evidence is very uncertain about the effect of smell training (olfactory training) on smell and taste loss in long COVID. Improvement · very low certainty C
Combination: Smell training (olfactory training)69 randomised
Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study. (2022): Smell Quantity, no clear difference.
Shown, not counted: smell training (olfactory training) was given together with other treatments.
Combination: Corticosteroid pulses + Smell training (olfactory training)78 in the study
Role of Oral Corticosteroid and Olfactory Training for Treatment of Post-COVID-19 Olfactory Dysfunction: Our Experiences (2021): Time of treatment / Number of patients recovered, better (not tested).
Shown, not counted: smell training (olfactory training) was given together with other treatments.
Olfactory Training Impacts Olfactory Dysfunction Induced by COVID-19: A Pilot Study. (2023)
Effect of Olfactory Training in COVID-19 Related Olfactory Dysfunction-A Placebo-Controlled Trial. (2025)
Olfactory Training for COVID-19–Related Smell Loss: The SMELL Trial (2026) preprint
Olfactory Training in the Treatment of COVID-19–Related Olfactory Disorders (2025)
Effects of classical olfactory training in patients with COVID-19-related persistent loss of smell. (2023)
According to their preference, participants were stratified into two groups
eight were excluded from the study due to missed follow-up (n = 4, two in the control group and two in the COT group) or insufficient commitment to the training scheme (n = 4).
whereby a third of eligible patients were assigned to the control group.
Real-World Outcomes of 3-Month Olfactory Training on Post-COVID-19 Parosmia. (2025)
Quality of Life and Chemosensory Function in Post-COVID Patients: Adherence to Olfactory Training. (2026)
OLFACTORY TRAINING EFFICIENCY IN POST-COVID-19 PERSISTENT OLFACTORY DISORDERS (2022) preprint
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.
Studies with no comparison group4 studies · 569 people with results
Quality of life improved.
The evidence is very uncertain about the effect of smell training (olfactory training) on quality of life in long COVID. Improvement · very low certainty C
Quality of Life and Chemosensory Function in Post-COVID Patients: Adherence to Olfactory Training. (2026)
OLFACTORY TRAINING EFFICIENCY IN POST-COVID-19 PERSISTENT OLFACTORY DISORDERS (2022) preprint
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (68 in all).
The randomised trial70 randomised · 68 analysed · 12 weeks · four-odor training set: citronellal (lemon), eucalyptol (eucalyptus), eugenol (clove), and phenyl-ethyl alcohol (rose), twice daily for 12 weeks; each odor for approximately 15 seconds
Overall symptoms improved more than in the comparison group.
The evidence is very uncertain about the effect of smell training (olfactory training) on overall symptoms in long COVID. Improvement · very low certainty C
Olfactory Training for COVID-19–Related Smell Loss: The SMELL Trial (2026) preprint
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design).
Studies with no comparison group65 in the study · 53 with outcome data · at least 3 months (mean OT duration 4.36 months · four odours: rose (floral), eucalyptus (resinous), lemon (fruity), clove (spicy); 30 s each, twice daily for at least 3 months
Smell and taste loss improved.
The evidence is very uncertain about the effect of smell training (olfactory training) on smell and taste loss in ME/CFS or long COVID. Improvement · very low certainty C
Retronasal Olfactory Function After Olfactory Training: A Prospective Single-Arm Study. (2026)
Outcomes that only studies of smell training (olfactory training) given together with other treatments looked at. Shown, not graded: they can’t tell what smell training (olfactory training) did alone.
Cognition (brain fog) Long COVID
Combination: Smell training (olfactory training)69 randomised
Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study. (2022): Memory, no clear difference.
Shown, not counted: smell training (olfactory training) was given together with other treatments.
1 discontinued the study (withdrew consentOlfactory Training for COVID-19–Related Smell Loss: The SMELL Trial (2026)
Seventeen were excluded (13 lost to follow-up, 2 reinfected, 2 withdrewWeb-application guided bimodal olfactory training for COVID-19 patients: a randomized trial. (2025)
None of the patients reported any side effects related to olfactory trainingEffects of classical olfactory training in patients with COVID-19-related persistent loss of smell. (2023)
At the end of the survey, only 3.75% of patients had discontinued treatment, one in the AOT group and two in the TOC groupIntensive Olfactory Training in Post-COVID Patients: A Randomized Multicenter Clinical Trial (2022)
All patients completed the study, and there were no adverse eventsTreatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial. (2023)
| Side effect | Studies that reported it |
|---|---|
| Worse symptoms or a flare | 2 studies |
| Headache | 1 study |
| Nausea or stomach upset | 1 study |
Reviews pool earlier studies. Each shows when it was published and how far its search went.
“we propose that OT should be the primary treatment in patients with persistent post-COVID-19 olfactory loss.”
Researchers conducted a double-blind randomized pilot study of olfactory training (OT) for post-COVID-19 olfactory dysfunction. A total of 50 participants were included, with 25 recruited per group. The intervention group sniffed 4 scents (rose, orange, clove, and eucalyptus) for 5 min twice daily for 12 weeks; the placebo group sniffed odorless propylene glycol. Objective olfactory function was measured with the UPSIT-40. At follow-up, 41 participants returned: 19 in the intervention group and 22 in the placebo group. UPSIT scores were 24.3 (7.01) before and 25.8 (7.95) after training in the intervention group, and 24.6 (5.58) before and 25.6 (6.13) after training in the placebo group; the authors report no significant effect of group or time and no interaction. For self-evaluation of smell and taste (0–10 points), they report a significant effect of time (p < 0.001). In the intervention group, self-evaluation of smell increased from 3.8 (1.9) to 5.4 (1.8) points (p = 0.002), and taste from 5.3 (2.5) to 6.5 (2.5) points (p = 0.01). In the placebo group, smell changed from 3.5 (1.8) to 4.2 (2.4) points and taste from 4.4 (2.6) to 4.9 (3.0) points, reported as ns. After training, parosmia was reported by 14/19 participants in the trained group and 21/22 in the placebo group (p = 0.049). Quality-of-life scores improved in both groups from 12.4 (SEM = 0.74) to 10.5 (0.78) points (p = 0.001), with no effect of group. The authors state OT has virtually no side effects; worsening and withdrawals were not reported.
This prospective randomized controlled study at Colombo South Teaching Hospital, Sri Lanka, compared olfactory training, intranasal corticosteroid, combined therapy, and observation in patients with persistent post-COVID-19 anosmia or hyposmia. It enrolled 81 patients, allocated to olfactory training (23), intranasal corticosteroid (19), combined therapy (20), or control/observation (19). Olfactory training was performed twice daily for a minimum of three months. The corticosteroid arm received betamethasone sodium phosphate 0.1% nasal drops twice daily. Smell-identification was measured with the Quick Smell Identification Test (QSIT; score 0 to 3) at baseline and monthly up to three months. Smell-identification scores improved progressively across all four groups over time. Among treatment groups, improvement from baseline was significant at one month (p < 0.001) and maintained at two months (p < 0.001). At one month, approximately 86% of Group I (20 of 23) showed measurable clinical improvement versus approximately 64% of Group II (12 of 19) (p = 0.0086). There was no statistically significant difference in one-month recovery between olfactory training alone and combined therapy (p = 0.2249). Improvement was greater in participants receiving an active intervention than observation alone. Side effects and withdrawals were not reported. The authors state limitations including a relatively small sample size, possible underpowering, a relatively short follow-up, reliance mainly on QSIT, and a single-centre design.
This preprint abstract reports a study of olfactory training in people with post-COVID olfactory disorder. The entire group consisted of 75 subjects (15 men and 60 women), randomly divided into two groups. Patients in both groups received pharmacological treatment (intranasal corticosteroids and vitamin A), salt irrigations, and elements of speech therapy olfactory training (SOT). Participants in the study group additionally carried out classical olfactory training (OT) using applicators with 4 scents twice a day. Olfactory function was assessed using the Sniffin Sticks' Test (SST). For total SST score, the mean change before and after intervention in the study group was 7.9 points (p < 0.001). In the control group, the mean change was 2.8 points (p = 0.006). The abstract reports no side effects, harms, or withdrawals for either arm, and it does not report how long treatment lasted or where the study took place. The authors conclude that classical OT appears to improve recovery from post-COVID OD compared to pharmacological therapy with SOT elements alone. They also state that intranasal corticosteroids, topical vitamin A, and saline nasal irrigation in their therapy seemed to help in improving olfaction, and that a multidisciplinary team used here – doctor, speech therapist, and psychologist – may have also contributed to the effectiveness of the therapy. No limitations are stated in the abstract.
This randomized, placebo-controlled, investigator-blinded, single-center trial enrolled 65 adults with COVID-19 induced olfactory dysfunction referred to Rigshospitalet, Copenhagen, Denmark, or recruited through an online advertisement. Participants were randomized 1:1 to olfactory training with four essential oils (orange, lavender, clove, and peppermint) or the same training with odor-free placebo oils, twice daily for 12 weeks, with each oil for 20 s with a 10 s interval. Olfactory function was measured with the Sniffin' Sticks extended TDI test at baseline and follow-up after the 12-week intervention; subjective olfactory function and self-rated quality of life were measured with a numeric rating scale. Forty-nine participants completed 12 weeks of training (OT n = 25; P-OT n = 24); there were 16 dropouts, seven from the OT group and nine from the P-OT group. The intervention group did not significantly improve olfactory function compared with the control group. Median TDI change was 1.50 in the OT group and 0.25 in the P-OT group; within-group p values were 0.224 and 0.429. Clinical improvement (≥5.5-point TDI increase) occurred in 3 out of 25 participants (12%) in the OT group and 4 out of 24 (16.67%) in the P-OT group (p = 0.702). Self-rated QoL improved in the OT group (p = 0.002) but not in the P-OT group (p = 0.113). Parosmia at baseline was associated with a decrease in TDI score by −3.98 points (p = 0.010). Side effects were not reported.
This prospective randomized clinical trial assessed olfactory training for persistent dysosmia following COVID-19, with 5 weeks' to 12 months' progression. Patients were divided between 2 groups: a classical 4-odor protocol (n=49) and an intensive 8-odor protocol (n=30). The setting was not reported. Training duration was not reported; olfaction was assessed at inclusion (V1) and at 4 and 8 months (V2 and V3) on the Sniffin' Sticks test, the DyNaChron self-reported olfaction questionnaire and a visual analogue scale (VAS). Both protocols significantly improved subjective olfactory assessment on VAS, with non-significant trends for improvement on psychophysical tests. There was no significant difference in olfactory recovery between the classic and intensive protocols. Adhesion to the training program decreased markedly beyond 4 months. Side effects and withdrawals were not reported. The authors concluded that intensive olfactory training did not increase the chances of olfactory recovery compared to the classic protocol in a population with persistent dysosmia following COVID-19 infection. Limitations were not stated.
This randomised study evaluated web-application-guided bimodal olfactory training with the MaMadeleine kit for persistent post-COVID-19 olfactory dysfunction. It enrolled 100 PACS patients aged 14 and older; 83 were included/analysed (43 group A, 40 group B). Group A did simple olfactory training with two random odours twice daily, up to 5 minutes each, 6 days/week for 2 months; group B did semantic training with three selected odours once daily for 10 minutes, six days/week for 2 months. Follow-up was 2 months (± 2 weeks) after V1. Outcomes included Sniffin’ Sticks Test scores, adherence and quality of life. Overall, subjective total quantitative olfactory function improved in 79.4% (n=58), and 58.9% (n=43) reported improvement in both ortho-nasal and retro-nasal function. TDI rose from 26.5±7.5 to 29.1±7.4 (p<0.001). Parosmia fell from 68 to 48 and phantosmia from 27 to 8; normosmic patients increased from 23 (27.7%) to 39 (47%) (p=0.003). Quality of life improved from 11.2±5.2 to 12.8±5.8 (p<0.001). There were no significant between-group differences in orthonasal or retronasal improvement, TDI change, ΔPPTT scores or Δ Short-QOD-NS; group A had more TDI improvement beyond MCID (41.8% [n=18] vs 20% [n=8], p=0.032). Mean adherence was 78.5±19.3% [18–100%], better in group B (83.6%±17.4%) than group A (73.7%±19.8%, p=0.010). Seventeen were excluded (13 lost to follow-up, 2 reinfected, 2 withdrew). No collected side-effect data are reported; a post-hoc analysis found significant worsening in the threshold subdimension in group A (p=0.049; PPTT-impaired n=10, 12%). Authors state limitations: randomization bias, no control group, 2-month duration, final sample 83 versus initial projection 100.
This pilot, randomised, controlled, open-label trial recruited long COVID patients with persistent olfactory dysfunction at two tertiary medical centres in Hong Kong. A total of 26 participants were randomly assigned to oral vitamin A 25,000 IU daily for 14 days combined with aerosolised diffuser olfactory training thrice daily for 4 weeks (combination group, n = 10), olfactory training alone (standard care group, n = 11), or clinical observation (control group, n = 5). Twenty-two trial participants were included in the primary analysis: combination group (n = 9), standard care group (n = 8), and control group (n = 5). Median duration of olfactory dysfunction at enrolment was 157 days (IQR 127–175) and mean BTT score at baseline was 2.3 (SD 1.1). Outcomes were measured at week 4. At end-of-treatment, mean BTT scores were significantly higher for the combination group than the control (p < 0.001, MD = 4.4, 95% CI 1.7 to 7.2) and standard care groups (p = 0.009, MD = 3.2, 95% CI 0.5 to 5.9); there were no differences in BTT scores between standard care and control groups (p = 0.229, MD = 1.3, 95% CI −0.9 to 3.4). SIT scores were significantly higher in the combination group after treatment (p = 0.009) but no differences were found in the standard care or control groups. No adverse events were reported; two patients in the standard care group were excluded from analysis due to withdrawal of consent.
This double-blinded, placebo-controlled multicenter randomized trial asked whether co-ultramicronized palmitoylethanolamide with luteolin (um-PEA–LUT), olfactory training, or both would change persistent COVID-19 olfactory dysfunction of >6 months’ duration at three referral hospitals from November 2021 to August 2022. From 250 patients enrolled, 202 completed the study. Patients received 90 days of olfactory training plus placebo (38 analysed), um-PEA–LUT once daily (48 analysed; one sachet containing palmitoylethanolamide 700 mg and luteolin 70 mg), um-PEA–LUT twice daily (40 analysed), or once-daily um-PEA–LUT plus olfactory training (76 analysed). The Sniffin’ Sticks odor identification test was scored at baseline and at 30, 60, and 90 days. At 90 days, ≥3-point improvement occurred in 89.2% (50 patients) with combined therapy, 41.6% (20) with once-daily um-PEA–LUT, 40% (16) with twice-daily um-PEA–LUT, and 36.8% (14) with olfactory training plus placebo (p < 0.00001). Subclinical improvement (<3 points) was more frequent with um-PEA–LUT alone than with olfactory training plus placebo (p < 0.0001). All 48 once-daily and all 76 combined-therapy patients improved; in the twice-daily group 30 of 40 (75%) improved, 6 (15%) were unchanged, and 4 (10%) worsened; in the control group 20 (52.6%) improved, 16 (42.1%) had no change, and 2 (5.3%) had a lower score. No adverse events were reported. Attrition was 19.2% (48 of 250).
The abstract notes that studies of long-term olfactory dysfunction are limited and that no randomised-controlled trials of early olfactory training have been conducted. It describes a prospective, multi-centre study of post-COVID olfactory dysfunction and long-Covid. It reports that 218 individuals with a sudden loss of sense of smell of at least 4-weeks were recruited, with baseline psychophysical measurements of smell and taste function. Eligible participants were further recruited into a 12-week RCT of olfactory training versus control (safety information). Patient-reported outcomes were measured using an electronic survey and BSIT at baseline and 12 weeks, and an additional 1-year follow-up was open to all participants. For the RCT comparison, the abstract states that the absolute difference in BSIT improvement after 12 weeks was 0.45 higher in the intervention arm. It does not report whether this difference was statistically significant, how many participants were analysed in each arm, or side effects and withdrawals. The authors conclude that early olfactory training may be helpful, although their findings are inconclusive, and they state that further studies to improve management are highly warranted.
This multicenter randomized clinical trial tested whether olfactory training can be intensified for persistent post-COVID-19 olfactory dysfunction. It screened 340 patients and enrolled 80 with olfactory alteration persisting at least 4 weeks after COVID-19 symptoms, in otorhinolaryngology services in Curitiba and Londrina, Brazil. Patients were randomly assigned in a 2:1 ratio to advanced olfactory training (AOT) with 8 essential oils (26 analysed) or classical olfactory training (COT) with 4 essential oils (54 analysed). Both trained over 4 weeks, each odor for 15 s twice daily with a 30-s interval, and were re-evaluated after 1 month. Assessments included the UPSIT and visual analog scales (VAS). In the whole study, mean UPSIT increased by 1.5 ± 3.9 points (P = .002), and 81.3% reported improved sense of smell. Between groups, UPSIT progression was 1.0 ± 4.2 with AOT and 1.7 ± 3.8 with COT (P = .281); final UPSIT was 27.2 ± 4.8 vs 26.4 ± 6.9 (P = .992); olfaction VAS at 1-month follow-up was 5.6 ± 2.2 vs 5.8 ± 2.1 (P = .499); subjective improvement was 84.6% vs 79.6% (P = .763). Side effect with OT was reported as yes in 18 (22.5%) and no in 62 (77.5%); headache, nausea, and worsening of nasal symptoms were the most commonly reported complaints. At the end, 3.75% discontinued treatment: one in AOT and 2 in TOC. The authors state limitations including the short treatment duration and UPSIT assessing odor identification only.
This multicenter randomized clinical trial asked whether olfactory training can be optimized by using more fragrances over a shorter period in people with persistent olfactory dysfunction after COVID-19. Eighty participants were enrolled and analysed; they were recruited through press and social networks and followed at otolaryngology services in Curitiba and Londrina. Participants were assigned to an advanced olfactory training set (AOT; n=26) with eight essential oils or a classical olfactory training set (COT; n=54) with four essential oils, each for four weeks, with each odor for 15 seconds twice daily. Smell was assessed with the University of Pennsylvania Smell Identification Test (UPSIT) and visual analogue scales before and after treatment. Overall, UPSIT increased by a mean 1.5 ± 3.9 points (p=0.002). Between groups, UPSIT score improvement was 1.0 ± 4.2 for AOT and 1.7 ± 3.8 for COT (p=0.281), and final UPSIT was 27.2 ± 4.8 versus 26.4 ± 6.9 (p=0.992), with no significant difference. Olfaction VAS at return was 5.6 ± 2.2 for AOT and 5.8 ± 2.1 for COT (p=0.499). Subjective improvement was reported by 81.3% overall, 84.6% in AOT and 79.6% in COT (p=0.763). Side effects with olfactory training were listed as Yes 18 and No 62; complaints were mild, without need to interrupt training, and included headache, nausea and worsening nasal symptoms. Treatment discontinuation was 3.75%, one in AOT and two in COT. A count of participants who worsened was not reported. The authors state the short treatment duration as the main limitation.
This prospective cohort study asked whether structured olfactory training changes chemosensory function in adults with persistent post-COVID syndrome and chemosensory impairment, recruited from a specialized post-COVID outpatient clinic. Of 29 patients who reported impaired smell and/or taste, 26 started training and 25 were included in the final efficacy analysis; 14 used Sniffin’ Sticks and 11 used patient-selected natural odorants. Training was twice daily for 12 weeks. There was no non-intervention control group, and the two training approaches were not designed to be formally compared. Outcomes included the Sniffin’ Sticks TDI, 16-item Taste Strips, a visual analogue scale (VAS), and the self-MOQ before and after training. Mean TDI was 19.0 ± 8.2 at baseline and 20.1 ± 10.5 after 12 weeks (p = 0.52). Taste scores were 6.2 ± 4.1 and 7.2 ± 4.7 (p = 0.11); VAS was 2.7 ± 2.3 and 2.4 ± 2.1 (p = 0.37); self-MOQ was 4.0 ± 1.4 and 4.2 ± 1.3 (p = 0.14). 5 patients showed clinically relevant improvement and 2 showed deterioration. 2 patients declined participation and 1 was lost to follow-up; no side-effect counts were reported. The authors state limits including no non-training control group, small sample, unmeasured adherence, possible practice effect, selection bias, and a limited observation period.
This prospective case-controlled study examined adults with post-COVID-19 long-lasting olfactory dysfunction. A total of 78 participants were studied: Group 1 had 29 patients with anosmia or hyposmia after COVID-19, Group 2 had 24 patients with normosmia after COVID-19, and Group 3 had 25 volunteers with no history of COVID-19 infection. Group 1 received olfactory training with four opaque vials each containing 5 ml of essential oils, inhaling each scent for at least 25 s twice a day for 12 weeks. The other groups received no intervention. Olfactory bulb morphology was measured with magnetic resonance imaging, and olfactory function was measured with Sniffin’ Sticks threshold, discrimination, and identification tests and TDI scores. Group 1 had smaller left and right olfactory bulb volumes than Groups 2 and 3 (p<0.001). After 12 weeks of olfactory training in Group 1, right olfactory bulb volume increased from 53.92±3.3 to 54.89±2.9 mm3 (p=0.002), left volume from 54.1±2.55 to 54.7±2.44 mm3 (p=0.021), and right thickness from 2.41±0.42 to 2.48±0.41 mm (p=0.036). TDI score rose from 22.5 to 32.5 (p<0.001), threshold from 7.2 to 9.5 (p<0.001), discrimination from 8 to 11 (p=0.002), and identification from 7 to 11 (p<0.001). Left thickness, right and left length, and sulcus depth did not change significantly. The paper reports no significant difference in olfactory bulb signal intensity post-OT (p<0.05) and that signal intensity changes were observed in only three patients following OT. No patients dropped out; side effects were not reported.
This prospective observational study examined olfactory training (OT) in people with persistent post-COVID-19 olfactory loss. Among 114 participants with post-COVID-19 olfactory loss, adherence to OT was 60%. Participants underwent 4 months of OT, and orthonasal olfactory function was assessed with the extended Sniffin' Sticks test battery while retronasal olfactory function was tested with powdered aromas at baseline and after training. The study compared adherents with non-adherents. In adherents, the average increase in composite TDI score was 6.0 points compared to 2.6 points in non-adherents. Fifty-seven percent of adherent participants achieved a clinically significant improvement in TDI score (≥ 5.5 points), compared to 22% of non-adherents. In retronasal olfactoryidentification, 56% of adherents achieved a clinically significant improvement (≥ 4 points), compared to 16% of non-adherents. No p-values or significance statements are reported for these comparisons. The abstract does not report side effects, harms, or withdrawals for harms. No worsening result is reported. The abstract does not state limitations. The authors conclude that adherence to a 4-month OT regimen can yield clinically meaningful improvements in both orthonasal and retronasal olfactory function among individuals with persistent post-COVID-19 olfactory dysfunction.
This prospective, controlled study examined classical olfactory training (COT) for persistent olfactory dysfunction after COVID-19 at a university rhinology clinic in Turkey. Fifty-one patients chose between COT (n = 31) and no treatment (control, n = 20); after exclusions, 43 were analysed (COT 25, control 18). Eight were excluded: four for missed follow-up (two control, two COT) and four for insufficient commitment to training. COT used four odorants (lemon, rose, cloves, and eucalyptus), each odor twice a day for 12 weeks; the control group received no treatment. Olfactory function was measured with the Sniffin’ Sticks test (TDI score, maximum 48 points) at baseline and 12 weeks. The primary outcome was a TDI increase of 5.5 points or more. Ten of 25 (40%) COT patients and 1 of 18 (6%) control patients met this threshold (p = 0.014). Mean TDI changed by 5.68 ± 2.78 in the COT group and 1.46 ± 3.19 in the control group; the within-group change was p < 0.001 for COT and p = 0.077 for control. TDI scores improved in all 25 (100%) COT patients and in 14 of 18 (78%) control patients; deterioration occurred in 4 of 18 (22%) control patients. Average adherence was 87%; four out of 29 patients did not reach the specified compliance rate and were excluded. None reported side effects related to olfactory training. Age, gender, duration of OD, parosmia, and initial TDI score had no effect on clinical improvement after COT (p = 0.567, p = 0.678, p = 0.818, p = 0.803, and p = 0.800, respectively).
This prospective study enrolled 475 patients with olfactory dysfunction after PCR-confirmed COVID-19 (mean age 47.4/SD 9.5 years). Participants received standardized olfactory training: 4 odors twice daily for about 30 seconds each, over at least 12 weeks, preferably 24 to 36 weeks. They were assessed 3 times with an average interval of 3 months using questionnaires on quality of life, chemosensory function, and training adherence. There was no control group. Before initial testing, 32.8% (n = 156) had engaged in olfactory training, but only 9.1% (n = 43) followed recommended standards. At the second testing, 31.1% (n = 106) adhered, decreasing to 18.6% (n = 43) at the final testing. Quality of life improved from 5.63 ± 2.37 initially to 4.85 ± 2.55 and 4.51 ± 2.66; subjective odor ratings improved from 4.47 ± 2.16 to 5.46 ± 2.42 and 5.92 ± 2.47, with significant differences between first and second and first and third testing (P < .001). These improvements were not associated with adherence. Adherent participants reported greater quality-of-life restriction at second testing (0.66-point difference, P = .027). No significant difference in subjective olfactory ability was found between adherent and non-adherent participants. Side effects were not reported; about half attended all 3 sessions, with unknown dropout reasons.
This prospective cohort study asked whether 3 months of olfactory training (OT) affects persistent post-COVID-19 parosmia. Thirty-eight patients at a tertiary smell and taste clinic were instructed to sniff four odors (lemon, rose, eucalyptus, clove) twice daily for at least 15 seconds each for 3 months; there was no placebo or no-OT control group. Assessments before and after OT included self-rated parosmia intensity and pleasantness, a structured parosmia questionnaire, the Sniffin’ Sticks Parosmia Test (hedonic range and direction), and Sniffin’ Sticks threshold, discrimination, and identification (TDI). After 3 months, 20 (52.6%) patients reported improvement in parosmia and 18 (47.4%) reported no change. Pleasantness improved (−2.0 vs −3.0, p = 0.027), hedonic range improved (2.4 vs 1.9, p = 0.023), and TDI improved (27.9 vs 25.2, p = 0.001), with improvements in discrimination (11.5 vs 10.5, p = 0.031) and identification (10.0 vs 9.0, p = 0.003) but not threshold (p = 0.114). Twelve (31.6%) patients achieved the MCID in TDI. Median compliance was 37.5%; 12 (31.6%) complied at least 70%, and 6 (15.8%) did not attempt OT. Harms were not reported. The authors note the small sample and no control group, and that spontaneous recovery may have contributed.
This single-arm prospective study enrolled 37 pediatric subjects with post-COVID-19 olfactory dysfunction confirmed by the University of Pennsylvania Smell Identification Test (UPSIT); 11 were male and 26 female, with mean age 15.6 (2.1) years. The time interval between COVID-19 and study entry was 5.3 (2.4) months. All subjects underwent olfactory training (OT) by sniffing 4 odorants (lavender, orange, peppermint, and eucalyptus) for 1 min twice a day for 3 months. Subjects had an odorant identification test (OIT) of the 4 odorants each visit, and a repeat UPSIT was administered at the 4th visit. The mean pre/post study UPSIT score improvement was 2.3 (4.7), p = .09. OIT scores between entry and 3 subsequent visits showed mean improvements of 1.8 (1.5), 1.8 (1.9) and 2.3 (1.9) odorants, respectively. There was no comparison group. Harms and withdrawals were not reported. The authors state that OT did not affect OD as measured by UPSIT but OIT scores improved during OT; they postulate that OT likely has a role in pediatric post-COVID OD recovery but that UPSIT likely is too rigid to detect disparate odorant improvement. Limitations were not reported in the abstract.
This online questionnaire study asked US residents about treatments for chemosensory impairment, mostly associated with long COVID but with other etiologies included. A total of 6,100 participants provided electronic informed consent and completed the survey; 5,815 indicated they resided in the United States, and 4,877 patients were included in the analysis. Participants rated treatments they had been prescribed—nasal steroids, oral steroids, nasal rinse, smell training, theophylline, alpha lipoic acid, omega-3, and platelet-rich plasma—as extremely effective, very effective, moderately effective, slightly effective, or not effective at all. The study did not administer treatments or include a comparison group; patients reported different olfactory training regimens and complied for different durations. The most consistent predictor of efficacy was age: the majority of those 40 to 60 and 60+ rated nasal and oral steroids, zinc, nasal rinse, and smell training only slightly effective or not effective at all. Nasal steroids were rated slightly effective or not effective at all by 91% of those 40 to 60 years and 93% of those 60+ years. Smell training was rated slightly effective or not effective at all by 89% of those 60+ and 91% of those 40 to 60 years; 790 individuals reported using smell training. Differences were not significant for theophylline or PRP but samples were small. Harms were not reported.
This prospective and descriptive study enrolled 72 COVID-19 patients with post-COVID olfactory dysfunction. All patients received topical intranasal corticosteroids and olfactory training; there was no comparison group. The study was conducted in patients diagnosed with COVID-19 infection by reverse transcription–polymerase chain reaction of the nasopharyngeal swab. The paper reports recovery counts at fixed times: 11 (15.27%) patients recovered after 2 weeks, 34 (47.22%) patients recovered after 3 weeks, and 20 (27.77%) recovered after 4 weeks, out of 72 patients. Three patients lost to follow-up during the treatment period. The paper does not report side effects. No worsening or stopping is described. Limitations are not reported. The authors conclude that intranasal mometasone spray and olfactory training are useful treatment options for post-COVID olfactory dysfunction.
This was a prospective single-group before–after cohort in the ENT division of Nice University Hospital. It included 43 patients with post-COVID-19 persistent olfactory disorders lasting more than 6 weeks (3 to 15 months); patients were mainly self-referred or referred by general practitioners or colleagues. All received a self-olfactory training with a dedicated kit, scheduled twice a day for 6 months, with a second consultation at 6 months ± 15 days. No control group was used. Patients performed 14.5 ± 9 weeks (~3.5 months) of training on average; the average compliance ratio was 53 ± 33%. Outcomes included the Sniffin’ Sticks Test TDI, VAS subjective recovery, Short-QOD-NS and SF-36. The mean TDI score increased from 24.7 (±8.9) before OT to 30.9 (±9.8) after OT (p < 0.001). T increased from 4.9 ± 3.9 to 8.7 ± 5.2 and I from 9.4 ± 4.1 to 11.0 ± 3.4 (both p < 0.001); D changed from 10.4 ± 3.0 to 11.2 ± 3.3 (p = 0.110). Normosmic participants increased from 11 (25.6%) to 27 (62.8%). The discussion prints 62.6% where the results print 62.8% for the post-OT normosmic proportion. The number reporting parosmia increased from 8 (18.6%) to 27 (62.8%) (p < 0.001), and 20 (46.5%) developed parosmia. Phantosmia changed from nine (20.9%) to 12 (27.9%) (p = 0.581). Withdrawals for harms were not reported. The authors state that no control group was used, citing major ethical concerns, and that the small sample size reduced the study strength.
This case report describes a previously healthy 26-year-old female medical student living in New York, NY, who developed long COVID after a presumed acute SARS-CoV-2 infection in March 2020, with a concurrent perceived early-disseminated Lyme disease infection. The three-year arc covers numerous trial-and-error treatments: a two-week regimen of doxycycline 100 mg twice a day, metformin escalation alongside diet modifications, graded compression stockings, breathing exercises, increases in caffeine and salt consumption with increased fluid intake, a horizontal cardio exercise program with rest periods, osteopathic manipulative treatment, cognitive behavioral therapy, sleep hygiene improvements, supplements (vitamin C, vitamin D, vitamin B12, B-complex, n-acetyl cysteine, turmeric extract), a two-dose Moderna mRNA COVID-19 vaccination course, and abortive headache therapies (Excedrin or Fioricet and prochlorperazine). The authors report a moderate reduction in cycle length and morning hypoglycemic symptoms with metformin, a moderate reduction in myalgias, headaches and scalp allodynia with osteopathic manipulative treatment, some relief of post-COVID headache, help with headache pain, orthostatic palpitations, fatigue and brain fog from abortive therapies plus caffeine, salt and fluid intake, moderate improvements in fatigue and brain fog in the first 24 hours after the first vaccine dose, moderate symptom alleviation from digital interventions, and small but recognizable differences in fatigue and cognition from sleep hygiene. No improvement in symptoms other than mild reduction in right shoulder pain followed the doxycycline regimen. Supplements provided no discernable benefit. The patient reports full recovery from long COVID with residual blurred vision and oligomenorrhea. Reported harms include worsening blurred vision, palpitations, heat intolerance and near-syncopal events; a moderate increase in fatigue and brain fog with a CGRP antagonist; fatigue exacerbation with traditional exercise rehabilitation; symptom re-exacerbations with compression stockings; and increased headache frequency and duration with n-acetyl cysteine. The abstract describes near-total remission.
This case series reports two patients with Long COVID and olfactory and gustatory complaints who presented to the authors’ clinic. Both received stellate ganglion block (SGB) with 6 ml solution containing bupivacaine (15mg) and triamcinolone (10mg), given right-sided then left-sided 48 hours apart; the second patient had the bilateral procedure repeated. Severity of complaints was rated on a numerical rating scale (NRS) from 0 to 10 before and after SGB. At 2 months after the procedure in Case 1, cacosmia and cacogeusia each changed from 10 to 1 (90% achieved improvement), fatigue from 7 to 0 (100%), impaired concentration from 8 to 1 (87,5%), sleep disturbance from 6 to 1 (83,3%), myalgia from 7 to 2 (71,4%), and headache from 5 to 0 (100%). At 2 months after the second procedure in Case 2, anosmia changed from 8 to 5 (37,5%), ageusia from 7 to 4 (42,9%), myalgia from 3 to 1 (66,7%), and headache from 2 to 0 (100%). The text reports 90% recovery in the first patient and around 40% recovery in the second patient. Horner’s syndrome developed in both cases. There was no comparison group. The authors state evidence is limited by a few case reports and call for well-designed, multicenter studies.
The report aimed to share observations on a small case series of adults with long-lasting post-COVID-19 smell dysfunction. Eight patients (5 females, 3 males) with smell dysfunction lasting 3+ months followed a 30-day olfactory training protocol with ten plant-derived essential oils at home. The protocol involved two sessions every day, one in the morning and one in the evening, each lasting approximately 15 min. There was no control group; the patients were assessed at baseline (T0) and at the end of treatment (T1) with the ASOF questionnaire. Mean Subjective Olfactory Capability changed from 3.6 to 5.6 out of 10 (p=0.016), Self-Reported capability of Perceiving specific odors from 1.8 to 3.0 out of 5 (p=0.008), and Olfactory-Related Quality of life from 2.9 to 3.9 out of 6 (p=0.044). None of the patients reported any adverse effect or discontinued treatment, and all patients reported the treatment was well tolerated. The authors state that there was no control group and that the report involved a limited number of patients with heterogeneous comorbidities; follow-up coincided with treatment duration, with no additional check-ups, and sources of observational bias cannot be excluded.
This preprint describes a technique and reports a single patient: a 22-year-old female with 24-month post–COVID-19 anosmia. She received platelet-rich plasma (PRP) injected into the olfactory cleft and middle turbinate, a total of 2.2 mL (1.2 mL right, 1.0 mL left), in one procedure after local anesthesia with xylocaine 10% spray. There was no comparison group. Outcomes were threshold, discrimination, and identification scores; Olfactory Disorder Questionnaire (ODQ) scores; patient perception of smell recovery; pain and annoyance on a visual analog scale; and complications. Baseline threshold, discrimination, and identification scores were 1, 8, and 0; at 2-month post-injection they were 16, 16, and 16 (48). The ODQ score was 51 at baseline and 73 at 2 months; parosmia was 10 then 11, life quality statement 32 then 47, and sincerity statement 9 then 15. The patient perceived recovery of smell sense at 3-week post-injection, and smell sense progressively improved to the 2-month consultation. Pain was 2/10 for blood extraction and 1/10 for injection; local anesthesia annoyance was 3/10. The procedure was done without complication and with mild pain. Withdrawals for harms were not reported. The authors state that future large cohort randomized controlled studies are needed.
This is a single case report (症例提示) of one patient with long COVID-associated brain fog seen at the author's post-COVID outpatient clinic in Japan. The patient was given high-frequency rTMS at 10 Hz, 1,200 pulses to each target site (bilateral occipital lobes and the right dlPFC), at an intensity of 90% of the minimum motor threshold required for upper-limb motor area stimulation, once weekly for 10 consecutive sessions. There was no comparison group and no randomisation. Brain fog improved markedly immediately after the first rTMS session. At the end of the 10th session, memory-related failures slightly remained while visuospatial failures were absent; the patient could read without difficulty and join conversations without stagnation, the planned demotion was withdrawn and he returned to full work. At follow-up 1 month after the end of rTMS there was no re-exacerbation of symptoms; fatigue was not entirely absent but recovered with one night's sleep, and clock drawing was correct. No adverse events occurred during the rTMS period. The authors state that many questions remain about the specific method — frequency, stimulation intensity, number of sessions and especially the stimulation site — and that their method is not considered optimal.
This case report described one 25-year-old female with delayed and prolonged post-COVID parosmia and dysgeusia; the authors presented their treatment experience. There was no comparison group. Treatments included prednisone 0.5 mg/kg for 8 days, nasal irrigation with saline solution three times a day for 10 days plus Mupirocin for 10 days, Gabapentin 300 mg orally every 8 hours for 1 month, Escitalopram 5 mg daily, multivitamins, and olfactory rehabilitation. A transfusion of 50 million mesenchymal stem cells of endometrial origin showed no evidence of improvement even 8 weeks after it. The first COVID-19 vaccine dose was followed by an improvement of 25% of the parosmia and dysgeusia in the 7 days after application. After the second dose, an olfactory test found 40%, compared with 2 of 16 odors (12%) identified earlier. The report described mild improvement with prednisone, gabapentin, nasal irrigations and olfactory rehabilitation, greater after the second vaccine dose; improvement in depression but minimal improvement in parosmia and dysgeusia. Harms and withdrawals were not reported. Follow-up was 12 months after suffering the condition, when parosmia and dysgeusia still persisted.
This prospective, non-randomised study was conducted from April 2021 to December 2021 at two university hospitals in Rome and Sassari. It included 40 patients with multiple sclerosis (MS) and 45 patients with long COVID and persistent olfactory disorders. All patients had nasal endoscopy and Sniffin’ Sticks testing at baseline and three months after treatment. The long COVID group received um-PEA-LUT (palmitoylethanolamide 700 mg plus luteolin 70 mg) with olfactory training for three months. The MS group received disease-modifying therapies (DMTs), including IFN-beta 1a, glatiramer acetate, fingolimod, dimethylfumarate, natalizumab, and teriflunomide. After three months, 71.2% (32 subjects) of the long COVID group recovered normal or borderline normal olfactory function, while 28.8% (13 patients) did not recover. The average TDI score in recovered long COVID patients was 34.3 ± 4.6. After treatment, no statistically significant differences were observed between the MS and COVID-19 groups. No side-effect data were reported. The authors state that the comparison used parallel populations with different underlying disorders, so differences may reflect disease profiles rather than treatment differences; they also note no inflammatory biomarkers, a small sample, differing age ranges, and small MS treatment subgroups.
In a longitudinal study at a tertiary referral hospital in Rome from April 2021 to October 2021, 69 patients (43 women, 26 men; average age 40.6 + 10.5) with long COVID olfactory dysfunction were allocated to three groups and randomized to PEA-LUT alone or with olfactory training. The groups were previously trained PEA-LUT plus olfactory training (10 patients), training-naïve PEA-LUT plus olfactory training (43), and training-naïve PEA-LUT alone (16). PEA-LUT was given as 700 mg plus 70 mg sublingually; olfactory training was three times daily; follow-up was T0, T1, T2, and T3 over 90 days. Outcomes were odor identification, parosmia, and mental clouding/memory. Across the cohort, odor identification improved from average 7.9 ± 3.1 at T0 to 10.7 ± 2.6 at T3 (Tukey p < 0.0001), parosmia from 5.7 ± 3.5 to 3.2 ± 2.6 (p < 0.0001), and mental clouding from 2.6 ± 3.4 to 1.5 ± 2.3 (p = 0.02). In the PEA-LUT-alone group, TDI improved from 9.6 ± 3.1 to 12.2 ± 2.5 (p = 0.02) and parosmia from 7.2 ± 2.6 to 3.2 ± 1.5 (p < 0.00001), but mental clouding did not differ significantly (p = 0.3). Between-group smell and parosmia comparisons showed no significant differences. The paper describes adverse-event provisions but reports no event counts or withdrawals due to harms.
This prospective and descriptive study included 78 (26.71%) patients with post-COVID-19 olfactory dysfunction (anosmia or hyposmia) out of 292 COVID-19 patients at a single tertiary care teaching hospital between April 2020 and May 2021. There were 46 male and 32 female patients, with ages from 18 to 62 years. All participants received a 10 days' course of 16 mg methylprednisolone twice daily combined with olfactory training (OT); they were advised to sniff rose, clove, and lemon for 20 s each, twice a day. There was no comparison group. Smell was assessed after 1 week, 2 weeks, 3 weeks, 4 weeks, and 6 weeks. Table 2 reported recovery as 0 in the first week, 11 (14.10%) in the second weeks, 34 (43.58%) in the third weeks, 24 (30.76%) in the fourth weeks, and 6 (7.69%) in the sixth weeks; 3 (3.84%) were lost to follow-up during the treatment period. The authors also stated that all patients revived their olfaction by 6 weeks except three patients who lost follow-up. Out of 78 patients, 5 (6.41%) reported minimal side effects such as abdominal pain, and no patients reported side effects to OT. The authors stated there is a crucial demand for further studies to corroborate this outcome.
A systematic review and network meta-analysis examined pharmacological treatments for long COVID in adults, including trials on COVID-19 symptoms related to long COVID. Records were searched in PubMed/MEDLINE, Cochrane Library, Embase, CINAHL, PsycINFO and Web of Science from the beginning of 2020 to October 31, 2022. The review included 129 studies: 109 RCTs and 20 observational studies. The number of patients enrolled or analysed in the review was not recorded in the extracted data, and treatment duration or follow-up was not reported. Treatments included ivermectin mucoadhesive nanosuspension nasal spray (Aref 2021, 114 patients; Aref 2022, 96 patients), oxaloacetate, anticoagulants, hyperbaric oxygen and others; comparisons were against control (placebo/SOC) or other interventions. Outcomes included mortality, hospital admission, ICU admission, mechanical ventilation, symptom recovery, adverse events, serious adverse events, major bleeding, olfactory scores and thrombotic events. The extracted results contained no between-group result. Recorded harms included higher adverse-event odds with high-dose zinc (OR=21.87, 95%CI [1.25, 383.45]), high-dose vitamin C (OR=56.11, 95%CI [3.26, 966.29]) and tocilizumab (OR=9.64, 95%CI [2.76, 33.75]); major bleeding with treatment-dose anticoagulants (OR=1.86, 95%CI [1.19, 2.89]) and increased ICU admission with propolis. Stopping or dose change was not reported. The authors stated that some results came from a single study or studies with high RoB.
This systematic review and meta-analysis included seven RCTs published between 2021 and 2024, with 525 adults with post-COVID olfactory dysfunction; 332 received PEA-LUT plus olfactory training and 203 received placebo plus olfactory training. The PEA-LUT regimen in the included trials was daily oral PEA 700 mg plus LUT 70 mg with OT, compared with placebo plus OT; average ages ranged from 39.5 to 45.5 years. Outcomes were TDI scores and overall response rate. The pooled TDI score was higher with PEA-LUT plus OT than with OT alone (SMD = 0.90; 95% CI: 0.24–1.58; P < 0.01). The overall response rate was also higher in the combination group (RD = 0.33; 95% CI: 0.01–0.64; P = 0.04). Two studies reported no adverse events in either group; the remaining studies did not report safety outcomes. The authors state that the limited number of RCTs and relatively small sample size constrain generalizability.
This systematic literature review followed PRISMA 2020 guidelines and searched PubMed/MEDLINE, Scopus, Web of Science, Embase, and Cochrane Library for studies published between January 2021 and June 2026. After eligibility screening and duplicate removal, 60 studies were selected for qualitative synthesis. The review concerned post-COVID-19 olfactory changes and analyzed evidence on diagnosis, prognosis, and therapeutic strategies. No primary participants were enrolled or treated by the review, so no study-level group sizes, treatment durations, or follow-up periods were reported. The review states that many patients experience spontaneous recovery, while a significant proportion develops persistent olfactory dysfunction. It reports that olfactory training presented the highest level of scientific evidence and is considered the primary therapeutic strategy. Pharmacological therapies and emerging approaches, such as palmitoylethanolamide combined with luteolin and platelet-rich plasma, have shown promising results but still require further validation. Objective diagnostic methods such as UPSIT and Sniffin’ Sticks were described as essential for assessment. No side effects, withdrawals, worsening, or between-group comparisons from this review's own study were reported. The authors state no limitations in the provided text.
This meta-analysis pooled 51 RCTs with 4026 participants with Long COVID, searching PubMed, Cochrane Library, Embase, Web of Science, SPORTDiscus (EBSCO), CINAHL (EBSCO), and Rehabilitation & Sports medicine source (EBSCO) to July 20, 2025. Trials compared exercise training, respiratory muscle training, telerehabilitation, tDCS, olfactory training, steroid sprays, or PEA-LUT with no intervention, standard primary care, or placebo; follow-up ranged from 14 to 180 days. Outcomes included cardiopulmonary function, exercise capacity, fatigue, dyspnea, and olfactory recovery. Exercise training showed significant better 6MWT (MD 83.20; 95% CI 52.04–114.37) and 30sSTS (MD 3.05; 95% CI 1.96–4.13), but no significant difference for HADS-depression, HADS-anxiety, SF-12-PCS, FVC (% predicted), FEV1, VE/VO2, VE, RER, or FEV1/FVC. Respiratory muscle training showed significant better 6MWT (MD 89.54; 95% CI 9.86–169.23) and MIP (cm H2O) (MD 19.69; 95% CI 10.14–29.24), with no significant difference for FVC, FEV1, MFIS, HADS, or MEP. Telerehabilitation showed significant better 6MWT (MD 34.14; 95% CI 2.54–65.74), 30sSTS (MD 1.41; 95% CI 0.67–2.15), and FSS (MD −1.59; 95% CI −2.64 to −0.53). tDCS showed significant lower MFIS-physical (MD −2.29; 95% CI −4.36 to −0.22). Olfactory training and steroid sprays showed no significant differences; PEA-LUT showed significant higher TDI Score (MD 4.66; 95% CI 2.16–7.15). No side-effect or withdrawal counts were reported; the authors noted exercise may pose a risk of symptom exacerbation in post-exertional malaise. They reported high risk of bias in 33 studies and high heterogeneity.
This systematic review aimed to identify and synthesise publicly available research testing treatments for mental health, cognition and psychological well-being in long COVID. It included 33 documents representing 31 studies and 2477 participants recruited across four continents. The studies covered 7 psychosocial, 5 pharmaceutical, 3 natural supplement, 9 neurocognitive, 2 physical rehabilitation and 5 integrated intervention studies; 11 were RCTs, 2 non-randomised controlled trials, 10 uncontrolled trials, 7 case studies or series and 1 qualitative study. Some controlled trials reported significant group×time interactions: vortioxetine for depression and health-related QoL but not cognition; hyperbaric oxygen for total cognition and psychological distress only; high-definition transcranial direct current stimulation for cognitive and psychosocial fatigue, anxiety and QoL; and a programme combining non-invasive cognitive stimulation and guided mindfulness for mental fatigue, anxiety, depression, mood disturbance and several cognitive domains. Other trials reported no significant group×time interaction, including an adaptogen formulation and the ReCOVERY app. Many uncontrolled studies reported significant prepost improvements, but the authors state these cannot be definitively associated with treatment without a control group. Counts of people who worsened or stopped and side-effect counts were not reported in the recorded data; the authors note many studies did not report adverse events.
This systematic review searched PubMed, Scopus, Web of Science, EBSCOhost and the Cochrane Library through 01 May 2024 for studies of olfactory training in chronic olfactory disorder persisting for 30 days or longer after COVID-19. Fourteen studies (1.596 participants) were included. Olfactory training alone was reported to improve olfactory function in several studies, though Bérubé et al. observed no effect on objective scores while subjective function improved from 3.8 ± 1.9 to 5.4 ± 1.8 (p = 0.002) and parosmia frequency fell from 16 to 14. Khan et al. reported responders in 37.6% of intervention arms versus 24% of controls, and 55% subjective improvement. In Di Stadio et al., 92% of the PEA-LUT group improved versus 42% of controls; mean TDI rose from 20.6 ± 7.9 to 29.8 ± 7.5, and 56% versus 10% reached a normal TDI. With cerebrolysin, recovery was complete in 61.5% and partial in 17%, with no recovery in the group practising olfactory and gustatory training only. Vitamin A plus OT improved BTT scores (MD = 4.4, 95% CI 1.7 to 7.2), while alpha-lipoic acid showed no significant difference in CCCRC score (p = 0.63). Corticosteroid results were conflicting. The review reports minimal side effects. Authors note only 14 studies and single-study evidence for some adjuvants.
This systematic review examined interventions for brain fog caused by long-COVID in adults with proven symptoms. It included 17 studies, including a case report of 1 patient and a cohort of 208. Interventions were rehabilitation (cognitive training, telerehabilitation, mindfulness-based programs), noninvasive brain stimulation (transcranial magnetic, direct current, alternating current stimulation, photobiomodulation), hyperbaric oxygen therapy, and PEA-LUT. Treatment duration varied; PEA-LUT was assessed three months after treatment. Some studies compared an intervention with control or treatment as usual, while others reported before-and-after changes. Outcomes included MoCA, MMSE, WAIS4, BNIS, NeuroTrax, CANTAB, TAP/AVLT, CAB, PEBL, and PDQ-D-5. Noninvasive brain stimulation studies all showed improvement in cognitive ability. Hyperbaric oxygen studies showed improvements in cognitive tests and brain perfusion. PEA-LUT improved PRMQ and MoCA scores in treated patients; in one trial mental clouding fell in groups 1 and 3 but not group 2. Rehabilitation results were mixed, with some studies reporting enhancement and others no significant improvement. Adverse effects were mild: scalp pain in 4 out of 23 patients after stimulation; after hyperbaric oxygen, barotrauma n=4, ear pain n=1, palpitations n=3, headache n=1, fever n=1. Rehabilitation and pharmacological treatment had no adverse effects. The authors state limitations include a limited number of studies and high heterogeneity.
This systematic review and meta-analysis examined treatments for post-COVID-19 olfactory dysfunction. Eleven studies with 1414 participants were included, and six studies with 916 participants were assessed in the meta-analysis. Treatments included intranasal corticosteroids (INCS), oral corticosteroids (OCS), olfactory training (OT), a PEA 700mg/Luteolin 70 mg supplement, intranasal insulin film and intranasal photobiomodulation. Outcomes included VAS, Sniffin' Sticks identification, TDI, CCCRC and recovery time. For INCS+OT versus OT, VAS showed no significant difference (MD 0.89, 95%CI -1.92 to 3.7, p=0.54, 2 RCTs); Sniffin' Sticks identification showed no significant difference at one month (MD 2, 95%CI -0.66 to 4.66, p=0.139) or two months (MD -1, 95%CI -2.83 to 0.83, p=0.281). For OCS+OT versus OT, TDI showed no statistical difference at one month (MD 3.2, 95%CI -0.13 to 6.52, p=0.06) or two months (MD 2.45, 95%CI -3 to 7.89, p=0.38 in 2 case-controlled studies). OT alone showed statistically significant improvement in smell score (MD 4.68, 95%CI 2.65-6.71, p<0.00001). Betamethasone drops had no significant effect on recovery time versus placebo (Hazard ratio 0.88, 95% CI 0.68-1.14; p=0.31). Two studies reported no side effect related to therapy; LeBon and Saussez reported minor OCS side effects, mainly insomnia, headache, and abdominal discomfort. None reported major adverse effects; no side effects related to OT were reported. Authors' stated limitations were short follow-up periods, a small number of well-designed studies, lack of a control group to assess true OT effects, and quality/heterogeneity.
This systematic review and meta-analysis examined CoUltraPEALut for Post-Covid Olfactory Dysfunction (PCOD). Five studies with 441 patients between treated and control groups were included; the meta-analysis combined three studies with 327 patients. Searches covered PubMed, Embase and Web of Science to 31 May 2023. Treatment was oral micronized PEA 700 mg plus Luteolin 70 mg once daily for 30 or 90 days, with olfactory training (OT), compared with OT plus placebo or OT alone. Outcomes were TDI/Sniffin’ Sticks scores, parosmia and mental clouding. D’Ascanio et al. reported significant TDI improvement versus control; De Luca et al. reported improvement in PCOD and mental clouding, more pronounced with PEA-LUT plus OT; Di Stadio 2022 reported greater TDI improvement versus control; Di Stadio 2023 reported significant efficacy for quantitative alterations versus OT alone but no significant between-group effect on parosmia; another Di Stadio 2023 report found higher TDI scores after treatment than baseline. Meta-analysis OR was 3.07 (95% CI 2.22–3.92; p<0.00001); random-effects OR 4.28 (95% CI −0.04, 8.60; p=0.05), with I2=89%. Side-effect and withdrawal counts were not reported. Authors state limitations including small sample size, follow-up 30 to 90 days, absence of placebo control and Italian populations.
This systematic review examined complementary and alternative medicine (CAM) for long COVID. The authors searched multiple databases and clinical trial registries and included 14 randomized controlled trials with 1195 participants. Trials tested self-administered transcutaneous auricular vagus nerve stimulation, olfactory training, dietary supplements, neuro-meditation, aromatherapy, inspiratory muscle training (IMT), concurrent training, and an online breathing and well-being program. The review reported that taVNS was associated with a mild-to-moderate effect in reducing mental fatigue symptoms; olfactory training improved subjective but not objective olfactory function and reduced parosmia; CoQ10 showed no significant difference from placebo for overall health status or post-COVID-19 symptoms; neuro-meditation improved fatigue, pain, mood, sleep, and cognitive functioning; aromatherapy improved post-COVID-19 fatigue; IMT improved breathlessness recovery, exercise capacity, and quality of life; concurrent training was associated with better outcomes than self-care recommendations and IMT alone; and L-arginine plus vitamin C improved walking performance, muscle strength, endothelial function, and fatigue. Reported harms included mild skin irritation, headache, dizziness, nausea, constipation, diarrhea, abdominal pain, heartburn, and muscle pain. One participant withdrew with headaches, one with dizziness, and seven with excessive fatigue. No serious adverse events were noted.
This systematic review asked what evidence exists on interventions for rehabilitation for COVID-19-related limitations of functioning in adults with COVID-19 or post COVID-19 condition (PCC). It included 53 RCTs with 3882 randomized participants; included adults were hospitalized or managed at home, and the review covered non-severe, severe, critical COVID-19 and PCC. Interventions were compared with usual care, sham/placebo, no treatment, or another active intervention; duration was not reported. Outcomes covered body functions, activities and participation, quality of life, and adverse events. The review synthesized evidence narratively. It reports that the effect of breathing and strengthening exercise programs on dyspnea and physical exercise capacity compared to no treatment in non-severe COVID-19 patients is uncertain. Multicomponent telerehabilitation may slightly increase physical exercise capacity compared to educational intervention in adults with PCC, but uncertainty remains about its effect on lung function and physical exercise capacity compared to no treatment; it reported no evidence of an effect on FVC and FEV1/FVC% for multicomponent telerehabilitation compared to no treatment in PCC. The effect of inspiratory muscle training on maximal inspiratory pressure compared to no treatment in adults with PCC is uncertain. For harms, four grouped studies and fourteen studies reported no adverse events; five and three mild adverse events (transient skin redness) occurred in active HD-tDCS and sham groups, respectively; one person in the sham group presented symptom exacerbation; olfactory training had two (0.8%) headache reports and one (0.4%) worsening parosmia report. The authors state they cannot provide robust suggestions for practice.
This systematic review asked whether rehabilitation treatments applicable in ambulatory care help adults with persisting symptoms after COVID-19. Searches on 9 May 2022 identified 45,479 records, and 38 studies comprising 2,790 participants were included. Interventions included physical training, breathing exercises, nutritional supplements, olfactory training, multidisciplinary treatment, and other treatments such as hyperbaric oxygen therapy; treatment duration was not reported. Comparisons varied, including low- versus high-intensity training in 76 men and advanced versus classical olfactory training in 80 patients. Outcomes included fatigue, dyspnoea, pain, physical capacity, pulmonary function, sensory function, quality of life, return to activities, functional capacity, and adverse events. Physical training and breathing exercises may reduce fatigue, dyspnoea, and chest pain and may improve physical capacity and quality of life, with very weak evidence; improvement was not demonstrated for muscle pain or return to work. Low-intensity training increased handgrip strength and quality of life compared with high-intensity training. Advanced olfactory training was not superior to classical training. Hyperbaric oxygen therapy can have beneficial effects on fatigue in one cohort of 10 patients. Side effects with olfactory training occurred in 18 out of 80 participants. Reported adverse events included hospitalisations, dizziness, symptom exacerbation such as fatigue, headache in one participant, and post-exertional malaise after exercise.
This systematic review asked which interventions improve long COVID-19 signs and symptoms. The authors searched PubMed, Embase, Scopus, and Web of Science through 15 May 2022 and initially found 1638 articles. After removing 1602 works based on title/abstract, they considered 35 full texts and included two intervention studies. One RCT included 12 participants with anosmia/hyposmia persisting ≥ 90 days after a negative COVID-19 nasopharyngeal swab. Participants received olfactory training/stimulation through Sniffin Sticks, administered twice every day in a 10-min session for 30 days, plus daily PEA/Luteolin oral supplement, and were followed up for 1 month. Controls received standard care. The Sniffin score mean change was 2 for controls and 4 for treatment; p = 0.01. The other RCT included 44 adult females affected by fatigue during long COVID-19 and followed them for two weeks. Aromatherapy was compared with standard care; people who inhaled the essential oil blend for 2 weeks had significantly lower fatigue scores, with significant results on subscales of global, behavioral, general, and mental fatigue as well as vigor. The review did not report side effects or withdrawals. The authors state that only two intervention studies were found and more intervention studies are needed.
This narrative review examined nutritional and exercise interventions for long COVID; it did not report its own cohort. It describes a single-site RCT with n = 151 participants; n = 98 received VitK2/D3 and n = 53 received standard of care, and participants who received Vit K2/D3 showed a 7.1% reduction in long COVID symptoms compared to control group. A randomized, double-blind, placebo-controlled trial with n = 80 patients (n = 40 post COVID patients; n = 40 placebo) gave 60 000 IU of Vitamin D weekly for 8 weeks; the vitamin D group showed significant improvements in CFQ, DASS-anxiety and ACE, but no significant changes were found PQSI, DASS depression, TMT, IL-6 or CRP levels; Table 2 entry 11 reported this vitamin D supplementation with very low side effects. A multicentre trial with n = 144 patients (n = 71 vitamin D3 group; n = 71 placebo group) gave a single oral dose of 200 000 IU Vitamin D3 and found no significant differences between Vit D3 and placebo group for listed symptoms and quality of life upto 1 year of follow up. Probiotic mixture VSL#3® reduced fatigue and significantly improved physical functioning and gasterointestinal symptoms. Stopping or worsening was not reported. The review states limitations in trial design.
This rapid review assessed evidence on management and treatment of pulmonary complications in post-COVID-19 condition (PCC). It included 73 unique records from published and grey literature; these comprised guidance documents, secondary studies and primary research studies. Included primary studies involved adults with PCC and pulmonary complications, with individual study sizes that included 28 and 871 participants. Interventions included IHHT plus standard rehabilitation, nirmatrelvir plus ritonavir, hyperbaric oxygen, systemic corticosteroids, and multicomponent exercise rehabilitation. Comparisons included standard rehabilitation, placebo plus ritonavir, sham treatment, nonsteroid care, and usual care or control. Outcomes included 6MWT distance, Borg and PROMIS dyspnoea, RAND-36 physical function, FEV1, FVC, FVC % pred, resting oxygen requirement and adverse events. Doehner 2024 reported a significant between-group difference in 6MWT distance favouring IHHT plus rehabilitation (p<0.001). Geng 2024 found no between-group difference in PROMIS dyspnoea (p>0.05). Kjellberg 2025 found no difference in RAND-36 physical function (p=0.277) or 6MWT distance (p=0.62) with hyperbaric oxygen versus sham. Ntiamoah 2024 reported significant improvements in FEV1, FVC and FVC % pred in the steroid group only. Torres 2024 reported FVC % pred improved from 52±0.17% to 60±0.20% (p=0.019) and resting oxygen requirement reduced (p=0.005), with no significant change in 6MWT distance (p=0.50). Seo 2025 reported diarrhoea in 80% of patients with nintedanib; Ora 2023 reported no adverse events with sodium pyruvate nasal spray. The authors state study quality and risk of bias were heterogeneous and findings should be interpreted with caution.
This narrative review asked which interventions have been studied for long COVID-associated neurocognitive deficits. It searched PubMed, Embase, and Scopus and included Twelve studies. Reports covered cognitive training, rTMS, exercise rehabilitation, antihistamines (fexofenadine and famotidine), Brainmax, PEA-LUT, aromatherapy, and CICT. For rTMS, one case study (n = 1) reported improved processing speed and perceptual reasoning scores; a case series (n = 4) reported that 3 of 4 participants improved on behavioral inhibition; a pilot case series (n = 23) reported a statistically significant increase in attention/concentration, memory, and planning/organizational abilities; and a case series (n = 12) reported a statistically significant increase in all four cognitive areas and FSIQ from 94.6 ± 10.9 to 104.4 ± 13.0. The REGAIN trial (585 adults; n = 298 intervention, n = 287 usual care) reported statistically significant improvement in health-related quality of life at 3 months and 12 months and in depression, fatigue, and sleep disturbance, but not in cognitive function at 12 months. Salvucci and colleagues (14 experimental, 13 control) reported that 43% of the experimental group reported vanishing of fatigue and 43% reported vanishing of brain fog; the control group reported no statistically significant improvements across symptoms. Brainmax versus placebo (15 and 15) showed a statistically significant reduction in MFI-20 scores and a slight increase in MoCA scores. CICT (n = 14; 80% of unemployed before CICT returned to work) reported improvements. Authors state limitations include absence of control group, low sample sizes, and no reported effect size calculations. Worsening, stopping, and side effects were not reported.
This scoping review synthesized 50 studies (27 intervention and 23 observational) in adults with long COVID-19, identified through database and manual searches. The review itself had no comparison group and no meta-analysis. Included studies examined vitamin D, multinutrient/nutraceutical formulations, amino acids and metabolic support, creatine, oxaloacetate, nitric-oxide boosters, gut microbiota-targeted therapies, and diet/lifestyle programs; comparisons included placebo, controls, or another formulation. Examples reported: in 80 people with post-COVID-19 syndrome, weekly vitamin D improved fatigue (p = 0.024), anxiety (p = 0.011), and cognitive function (p = 0.012), with no effects on depression, sleep quality, or inflammatory markers. A single 200,000 IU vitamin D3 dose in 144 hospitalized patients showed no benefit on persistent symptoms or quality of life. Magnesium plus vitamin D improved depression (73.2% vs 34.5% remission, p = 0.006). PIRV-F20 in 44 long COVID-19 patients improved six-minute walking distance (+40 m vs +10 m, p = 0.02) but not strength or symptoms. Noni in 188 post-COVID-19 patients reduced fatigue (61.5% vs 24.3%), cognitive symptoms (59.4% vs 21.6%), and joint pain (66.2% vs 33.8%). SIM01 in 463 individuals alleviated core symptoms (all p < 0.01). Beetroot juice in 31 patients showed no significant between-group differences. Side effects and withdrawals were not reported in the recorded data. The authors state no formal quality appraisal was performed and causal inferences cannot be made.
This meta-narrative review evaluated pharmacologic and nonpharmacologic treatments for long COVID, defined as persistent symptoms 4 weeks or longer after acute COVID-19. The authors searched English-language articles from November 2019 through December 2023 and included 51 studies. Most included studies reported nonpharmacologic treatments, with fatigue the most prevalent symptom. Interventions described included therapeutic exercise, nutritional supplements, oxygen-ozone autohemotherapy, rehabilitation, molecular hydrogen therapy, hyperbaric oxygen, epipharyngeal abrasive therapy, Qingjin Yiqi granules, pomegranate juice with sumac, remdesivir, antibody-based therapies, and intranasal corticosteroids. Findings varied by study: some reported improvements in fatigue, dyspnea, cognitive symptoms, chest pain, immunodeficiency, or olfactory dysfunction. The review also reported no significant reduction in number or severity of long COVID–related symptoms with high-dose CoQ-10 compared with placebo; no significant difference in symptoms and mortality risks between nirmatrelvir/ritonavir and no treatment groups; smell score differences not statistically significant with corticosteroid nasal irrigation; and no effect of olfactory training on olfactory test scores. In Pehlivan et al., 6 cases were dropped for several reasons. The authors state the evidence is limited and of low quality.
This paper is a Literature Review, not a primary study. No participants were enrolled or analysed, no setting or participant source is reported, and no follow-up period, comparison arm, or harms data are given for the review’s own cohort. The review discusses long COVID and the Mediterranean diet as a nutritional suggestion. It summarizes a named study by Di Stadio, et al. (2022), described as a “multicenter study” in “people with olfactory impairment post-COVID-19 infection.” In that named study, the review states that these people “showed magnitude recovered after being given ultramicronized palmitoylethanolamide and luteolin during olfactory training compared to the control group.” The supplied text reports no participant numbers, treatment duration, or side-effect counts for that named study. The review’s conclusions concern the Mediterranean diet and related nutritional components: “nutritional modulation may be a potential therapeutic approach for long COVID management strategies”; natural bioactive in the Mediterranean diet “is suggested to reduce LC burden”; fibre- and antioxidant-rich foods “could help alleviate LC symptoms”; high-antioxidant foods “can help tackle chronic inflammation”; and flavonoids “act on anti-viral activity.” The authors state that “Mechanisms underpinning long COVID-19 are still not fully understood,” that “the relationship between nutrition and inflammation is quite complex,” and that “Recently, effective treatments for long COVID-19 have not been established.”
This evidence map updated a review of interventions for rehabilitation of post-acute COVID-19 sequelae in people who had symptomatic COVID-19 and post-acute sequelae; the population was predominantly adults. The update searched Biblioteca Virtual em Saúde and PubMed and was dated 27 July 2022. It included 32 review studies. Interventions were grouped as multimodal, pharmacological, therapeutic, and complementary therapies; no single treatment duration was reported. There was no comparison group; the map plotted associations between interventions and health outcomes. Effects were classified as positive, potentially positive, inconclusive, not informed, or no effect. The map reported 166 associations; the update analysed 69 associations. Exercise (isolated, multicomponent, or multimodal) had 23 positive effects and four potentially positive effects. Exercise prescription was reported with positive effects for functional exercise capacity, lung function, and quality of life; exercise had positive effects for mental health, dyspnoea, fatigue, exercise capacity, and muscle strength, while depression was not informed and lung function was absent and functional independence inconclusive. Pharmacological and complementary interventions for sensory functions had 15 associations. No study reported negative or potentially negative effects. Worsening, discontinuation, and side-effect counts were not reported. The authors state the literature remains incipient and many included items were protocols.
This comprehensive review asked how a treatable traits approach could be applied to long COVID. It combined an umbrella review of 22 systematic reviews identifying long COVID symptoms and complications with a systematic review of 18 randomized controlled trials of prevention or management. The trials tested many interventions, including metformin for 14 days during acute COVID-19 versus placebo, hyperbaric oxygen therapy versus sham, exercise training or respiratory muscle training versus usual care or sham, HD-tDCS versus sham, L-arginine plus liposomal vitamin C versus placebo, aromatherapy versus inert oils, and platelet-rich plasma injections versus saline. Outcomes included long COVID incidence, cognition, olfaction, dyspnoea, fatigue, exercise capacity and health-related quality of life. In one prevention trial, metformin was associated with reduced long COVID incidence at 10 months (hazard ratio 0.58 [95% CI 0.38, 0.88]) among 564 metformin and 561 placebo participants; ivermectin and fluvoxamine showed no significant benefit. For management, hyperbaric oxygen improved cognition compared with sham (104.1 ± 7.2 versus 101.3 ± 8.9, p = 0.038), and exercise training improved exercise capacity compared with exercise advice (38.9 ± 10.8 versus 36.1 ± 9.5 mL/kg/min, p = 0.035). Some studies found no significant between-group differences, including a larger exercise trial. Adverse events included 13 during hyperbaric oxygen versus 14 during control; one aromatherapy participant withdrew on day 13 with headaches, and one sham IMT participant withdrew for symptom exacerbation. The authors state the review was limited by not conducting a meta-analysis and by heterogeneity of the included systematic reviews.
This literature review examined treatments for post-COVID-19 olfactory dysfunction (OD). The authors searched PubMed and Google Scholar; it is not a new trial, and no numbers of enrolled, started, or analysed participants are reported. The review describes studies of corticosteroids, antioxidants (ALA, RA, omega-3 fatty acids, CoUltraPEALut), zinc, intranasal insulin, olfactory training (OT), nasal saline irrigation, stem cells and peptides, and platelet-rich plasma. It reports that 61% of patients with postviral OD had a modest improvement in olfaction after ALA in a prospective uncontrolled trial. It reports significantly improved odor threshold with omega-3 fatty acids, and that CoUltraPEALut was superior to OT alone when combined with OT for olfactory recovery. Zinc was associated with a significantly lower olfactory recovery time than no zinc. Intranasal insulin was associated with significant increases in olfactory recognition values and detection scores; the review also records that intranasal insulin has no side effects and does not raise blood glucose levels. OT improved olfactory scores and the rate of OD decreased significantly; higher objective scores correlated with persistence of OT over a follow-up of 1 and a half years. Platelet-rich plasma produced significant improvement in olfactory discrimination after 3 months. No worsening or stopping is reported. The authors conclude that overall efficiency is not yet satisfactory. They state limited research on COVID-19 OD.
This review presents the literature on management of post-COVID-19 olfactory dysfunction (PCOD), using PubMed/MEDLINE, EMBASE, and Cochrane searches. It summarized studies of olfactory training (OT), intranasal corticosteroids (ICS), and oral corticosteroids (OCS). Denis et al. reported 548 patients with at least 1 month of PCOD; 64% showed clinically significant improvement after a mean OT of 28 days. In Abdelalim et al., 50 patients received MFNS plus OT and 50 received OT alone for 3 weeks; VAS smell scores improved in both groups (P < 0.001), with no significant differences between groups after 1, 2, or 3 weeks. Average time to complete recovery was 26.4 days with MFNS + OT versus 26.2 days with OT alone (P = 0.88); complete recovery was 62% versus 52% (P = 0.31). Le Bon et al. compared 9 patients given a 10-day OCS + OT course with 18 given OT alone and found greater TDI improvement with OCS + OT (P = 0.046). Vaira et al. reported 18 patients had no improvement at 20 days but greater improvement at 40 day evaluations. Singh et al. reported improved anosmia and dysgeusia with ICS over control (p < 0.001). Kim et al. reported recovery rates of 28.2%, 54.8%, and 55.0% at 1-month follow-up (P < 0.001). Hura et al. noted minimal ICS side effects (local irritation, epistaxis); Le Bon et al. reported 3 patients with mild OCS side effects including abdominal pain and insomnia.